In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2018–19 season: Comparison with the 2010–11 to 2017–18 seasonsHideyuki Ikematsu, Seizaburo Kashiwagi, Naoki Kawai et al.|Journal of Infection and Chemotherapy|2020Cited by 24
Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019–2020 influenza seasonYong Chong, Hideyuki Ikematsu, Naoki Kawai et al.|Antiviral Research|2021Cited by 16
Duration of fever and PA/I38X-substituted virus emergence in patients treated with baloxavir in the 2018–2019 influenza seasonHideyuki Ikematsu, Kenichi Doniwa, Naoki Kawai et al.|Journal of Infection and Chemotherapy|2019Cited by 10
Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022–2023 seasonTakeyuki Goto, Hideyuki Ikematsu, Naoki Kawai et al.|Antiviral Research|2024Cited by 9
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2017–18 season: Comparison with the 2010–11 to 2016–17 seasonsHideyuki Ikematsu, Seizaburo Kashiwagi, Naoki Kawai et al.|Journal of Infection and Chemotherapy|2019Cited by 9